The pharmacological chaperone AT2220 increases the specific activity and lysosomal delivery of mutant acid alpha-glucosidase, and promotes glycogen reduction in a transgenic mouse model of Pompe disease.

Similar Items

• The Pharmacological Chaperone AT2220 Increases the Specific Activity and Lysosomal Delivery of Mutant Acid Alpha-Glucosidase, and Promotes Glycogen Reduction in a Transgenic Mouse Model of Pompe Disease
  od: Khanna, Richie, i dr.
  Izdano: (2014)
• The Pharmacological Chaperone AT2220 Increases Recombinant Human Acid α-Glucosidase Uptake and Glycogen Reduction in a Mouse Model of Pompe Disease
  od: Khanna, Richie, i dr.
  Izdano: (2012)
• The Pharmacological Chaperone 1-Deoxygalactonojirimycin Reduces Tissue Globotriaosylceramide Levels in a Mouse Model of Fabry Disease
  od: Khanna, Richie, i dr.
  Izdano: (2009)
• The Pharmacological Chaperone Isofagomine Increases Activity of the Gaucher Disease L444P Mutant Form of β-Glucosidase
  od: Khanna, Richie, i dr.
  Izdano: (2010)
• Improved efficacy of a next-generation ERT in murine Pompe disease
  od: Xu, Su, i dr.
  Izdano: (2019)